Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO

Journal of Cellular Biochemistry

Volumn 110, Issue 6, 2010, Pages 1495-1503

  Chen, Meng Ching ^a   Yu, Ching Han ^a,b   Wang, Shyi Wu ^c   Pu, Hsiao Fung ^a   Kan, Shu Fen ^a   Lin, Lie Chwen ^d   Chi, N Wen ^e   Ho, Lary Low Tone ^e   Lee, Chen Hsen ^e   Wang, Paulus S ^a,d,f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Evodiamine; G2 M arrest; Thyroid cancer cell line ARO

Indexed keywords

CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2 P161; CELL CYCLE PROTEIN 25C; CYCLIN B1; EVODIAMINE; RUTAECARPINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG EFFECT; PRIORITY JOURNAL; THYROID CANCER; UNDIFFERENTIATED CARCINOMA;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EVODIA; G2 PHASE; HUMANS; IN SITU NICK-END LABELING; INDOLE ALKALOIDS; PLANT EXTRACTS; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; THYROID NEOPLASMS; TIME FACTORS;

CITRUS MAXIMA;

EID: 77955474313     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22716     Document Type: Article

References (43)

1. Bhalla KN. 2003. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086.
2. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T. 1997. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 57:130-135.
3. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M. 1999. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274:22932-22940. (Pubitemid 129529118)
4. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. 2004. Cell death by mitotic catastrophe: A molecular definition. Oncogene 23: 2825-2837. (Pubitemid 38638845)
5. Chiou WF, Liao JF, Chen CF. 1996. Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J Nat Prod 59:374-378.
6. Ciliberto A, Lukacs A, Toth A, Tyson JJ, Novak B. 2005. Rewiring the exit from mitosis. Cell Cycle 4:1107-1112.
7. Collins I, Garrett MD. 2005. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5:366-373. (Pubitemid 40932038)
8. Fadeel B, Orrenius S. 2005. Apoptosis: A basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258:479-517. (Pubitemid 41705391)
9. Gimm O. 2001. Thyroid cancer. Cancer Lett 163:143-156.
10. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. 2000. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605. (Pubitemid 30115197)
11. Harris PE. 2002. The management of thyroid cancer in adults: A review of new guidelines. Clin Med 2:144-146.
12. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-776.
13. Huang YC, Guh JH, Teng CM. 2004. Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci 75:35-49. (Pubitemid 38501763)
14. Janss AJ, Maity A, Tang CB, Muschel RJ, McKenna WG, Sutton L, Phillips PC. 2001. Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin. Neuro Oncol 3:11-21. (Pubitemid 33685581)
15. Kan SF, Huang WJ, Lin LC, Wang PS. 2004. Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 110:641-651. (Pubitemid 38746021)
16. Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ, Wang PS. 2007. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cell Biochem 101:44-56.
17. Kobayashi Y, Nakano Y, Hoshikuma K, Yokoo Y, Kamiya T. 2000. The bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of Evodia rutaecarpa, on guinea-pig isolated bronchus: Possible involvement on vanilloid receptors. Planta Med 66:526-530. (Pubitemid 30627540)
18. Li XK, Motwani M, Tong W, Bornmann W, Schwartz GK. 2000. Huanglian, A Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol Pharmacol 58:1287-1293.
19. Liao CH, Pan SL, Guh JH, Chang YL, Pai HC, Lin CH, Teng CM. 2005. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ ADR-RES cells in vitro and in vivo. Carcinogenesis 26:968-975.
20. Lin H, Tsai SC, Chen JJ, Chiao YC, Wang SW, Wang GJ, Chen CF, Wang PS. 1999. Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 48:1532-1535.
21. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. 2007. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist Updat 10:13-29.
22. McDaid HM, Horwitz SB. 2001. Selective potentiation of paclitaxel (taxol)- induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 60:290-301.
23. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR. 2001. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 130:1028-1034.
24. Pasieka JL. 2003. Anaplastic thyroid cancer. Curr Opin Oncol 15:78-83.
25. Pines J. 1995. Cyclins, CDKs and cancer. Semin Cancer Biol 6:63-72.
26. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675-1687.
27. Senderowicz AM. 2004. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16:670-678.
28. Sherman SI. 2003. Thyroid carcinoma. Lancet 361:501-511.
29. Shin YW, Bae EA, Cai XF, Lee JJ, Kim DH. 2007. In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents. Biol Pharm Bull 30:197-199.
30. Sima AA, Li ZG. 2005. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 54:1497-1505.
31. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R. 2003. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63:6784-6790.
32. Steel RD, Torrie JH. 1980. Principles and procedures of statistics. New York: McGraw-Hill.
33. Tsai TH, Lee TF, Chen CF, Wang LC. 1995. Thermoregulatory effects of alkaloids isolated from Wu-Chu-Yu in afebrile and febrile rats. Pharmacol Biochem Behav 50:293-298.
34. Vini L, Harmer C. 2002. Management of thyroid cancer. Lancet Oncol 3:407-414.
35. Wang C, Wang MW, Tashiro S, Onodera S, Ikejima T. 2005. Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death. J Pharmacol Sci 97:494-500.
36. Yang J, Wu LJ, Tashino S, Onodera S, Ikejima T. 2008. Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic Res 42:492-504.
37. Yang ZG, Chen AQ, Liu B. 2009. Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205). Chem Biodivers 6:924-933.
38. Yeh JY, Huang WJ, Kan SF, Wang PS. 2001. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol 166:1937-1942.
39. Yeh JY, Huang WJ, Kan SF, Wang PS. 2003. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54:112-124.
40. Yoshizumi M, Houchi H, Ishimura Y, Hirose M, Kitagawa T, Tsuchiya K, Minakuchi K, Tamaki T. 1997. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J Med Invest 44:79-82.
41. Yu PL, Chao HL, Wang SW, Wang PS. 2009. Effects of evodiamine and rutaecarpine on the secretion of corticosterone by Zona fasciculata-reticularis cells in male rats. J Cell Biochem 108:469-475.
42. Zhang Y, Wu LJ, Tashiro S, Onodera S, Ikejima T. 2003. Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol Pharm Bull 26:1543-1547.
43. Zimmermann KC, Bonzon C, Green DR. 2001. The machinery of programmed cell death. Pharmacol Ther 92:57-70.